In the latest state effort to peel back the curtain on drug pricing, Nevada has adopted a law that requires pharmaceutical companies to disclose prices and costs associated with their asthma medicines, a step that mirrors action taken two years ago on diabetes treatments.

Specifically, drug makers must submit reports to the state detailing costs for producing or acquiring medicines used to treat asthma, as well as profit margins, any financial assistance provided to patients, and the factors contributing to recent, significant price increases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy